FDA Declines Merck 'Guided Missile' Lung Cancer Drug
Favicon 
www.newsmax.com

FDA Declines Merck 'Guided Missile' Lung Cancer Drug

The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles."